



News Nuus Izindaba

Newsletter of the South African Tuberculosis Vaccine Initiative **OCTOBER 2014**



SATVI receives accreditation from USA based clinical trial network
See Page 6



SATVI colleagues bid farewell to Professor Hanekom
See Page 2



CANSA TEA
20 September 2014

Inside

3	SATVI accredited as UCT Research Site.	14	The adventures of Dudley the SATVI Bear
4	Research grant from Medical Research Council	16	Nelson Mandela Day- Worcester
5	Report on 4th TB Conference, Durban	17	Staff Achievements
7	Boland Research Community Advisory Board	18	Visit from Bill Gates Foundation
8	Unique training program developed	19	CANSA Tea Day
11	Staff Teambuilding- August 2014	20	IDM Ten year Symposium
13	Research Publications		

JUNE 2014: PROFESSOR HANEKOM DEPARTS FROM SATVI TO FOCUS ON GLOBAL TB STRATEGY



SATVI Director,
Associate Professor
Mark Hatherill



Doctor Angelique Luabeya, Mrs Marwou de Kock, Prof Mark Hatherill, Prof Willem Hanekom and Mrs Lana Keyser



Professor Val Mizrai- (IDM) and Professor Willem Hanekom



Worcester SATVI staff with Professor Willem Hanekom

Professor Willem Hanekom, who has been with the South African Tuberculosis Vaccine Initiative (SATVI) for the past eight years, recently said his farewell to staff, friends and colleagues at the University of Cape Town, before taking up a key position at the Bill and Melinda Gates Foundation, where he will be focusing on the development of a global policy for TB vaccine development.

Willem who has been appointed Deputy Director, Program Head for TB Vaccines, at the Seattle based Bill Gates Foundation, was the Director of SATVI since 2011 and has vast expertise in clinical trials involving protective host responses to TB and has contributed to more than 120 publications. Willem is past president of the Federation of African Immunological Societies, and has served on multiple international advisory committees in TB vaccine development and translational immunology.

According to Associate Professor Mark Hatherill, Director of SATVI, who spoke at his farewell function, "Willem is respected by international scientists and the new position he assumes at the

Gates Foundation provides an opportunity for him to direct and give input into TB vaccine research at a global level. Within the scientific community everyone is aware of Willem's association with SATVI, the work that SATVI does and therefore he would play an important role as brand ambassador for SATVI within the global TB vaccine research community".

Dr Zameer Brey, SATVI Chief Operating Officer, thanked and applauded Professor Hanekom for his contribution on many levels. "Willem is an excellent teacher, mentor and role model. He has an inspirational leadership style and has a way of bringing out the best in people working with him. At an organisational level, Willem was instrumental in building a legacy for SATVI underpinned by a clear strategy, a focus on systems for long term sustainability and the recognition that people are core to any organisational success. Finally, his contribution to the TB vaccine world and the fight against TB is evidenced by his phenomenal publication record, successful grant proposals and by the multiple advisory groups he provides council to globally." Mrs Ashley Veldsman, Regulatory

Specialist at SATVI, told us that whilst it was sad to see him go, "that it was in effect an accolade and recognition of the calibre of people and research which SATVI and UCT delivers and that his departure would serve as an important North-South collaboration, not just to showcase what SATVI is capable of, but also what the African continent can offer the world".

In his address Professor Hanekom, told SATVI staff he finally decided to join the Foundation when, as researcher, faced with the challenge of a watershed in tuberculosis research at global level, he realised that there is a need for a rethink on how we work together internationally, the need for developing new scientific approaches, new ways of conducting clinical trials; and that he saw the opportunity to join the Gates Foundation to work on a global strategy towards eradicating TB through the development of a vaccine. According to him it would take two to three years to develop and implement such a strategy.

He commended SATVI staff that there was no other group as good as SATVI in getting research done, completing the research and producing results.

AUGUST 2014: SATVI ACCREDITED AS UCT RESEARCH CENTRE

The South African Tuberculosis Vaccine Initiative (SATVI) has joined the ranks of established UCT research groupings with the recent approval of its accreditation as a Research Centre of the University of Cape Town. According to the Associate Professor Mark Hatherill, the "accreditation offers major benefits for the organisation, which will gain from an improved governance environment, five-yearly cycles of strategic review, and the potential to leverage



is a dynamic group of clinical and laboratory scientists, which has been extraordinarily productive in terms of clinical trial activities, having conducted sixteen Phase 1-2b clinical trials of seven novel TB vaccine candidates, among more than 3,000 research participants, in addition to TB epidemiological studies involving more than 20,000 participants, during the last 14 years. The group's publication output, since 2006, totals 114 co-authored papers, with an average Impact Factor >4, of which 75 have had a SATVI first or senior author.

The SATVI postgraduate student program has also produced nine (9) PhD graduates and nine (9) Masters graduates during the same period. SATVI recently published the findings of the first efficacy trial of a new infant TB vaccine (MVA85A) in almost 50 years

(Tameris/Hatherill, Lancet 2013). This groundbreak in g clinical trial brought the group t o international promi nence and secured its position as the preferred clinical trial partner to test the safety, immunogenicity, and efficacy of new TB vaccines in the development pipeline.

SATVI's academic and administrative hub, and state-of-the-art immunology laboratory, lie within the Institute of Infectious Disease & Molecular Medicine (IDM) of the Faculty of Health Sciences, and are complemented by extensive clinical and laboratory facilities at the SATVI field site in Worcester, 110km from Cape Town.



Associate Professor Mark Hatherill announcing accreditation to SATVI staff. 8 August 2014



additional funding for students and post-doctoral fellows.

The South African Tuberculosis Vaccine Initiative (SATVI), established in 2001 by Professor Greg Hussey,



UPDATE ON VACCINE TRIAL

Aeras 404 Adolescent Trial well under way

The second phase of the Adolescent Vaccination Trial Aeras 404 is well under way with the SATVI team reaching out to local high schools to promote participation in this vaccine trial. The aim of the study is to enrol 1000 participants by 2015 targeting adolescents between the ages twelve and seventeen (12-17) who will participate in the study which will take two and half years.


Principal Investigator:

Associate Professor Mark Hatherill

Study Coordinator:

Sister Frances Ratangee

SATVI AWARDED RESEARCH GRANT BY THE MEDICAL RESEARCH COUNCIL



Associate Professor Tom Scriba discussing research with Doctoral student Richard Baguma

Associate Professor Thomas Scriba, from the South African Tuberculosis Vaccine initiative (SATVI) has secured a research grant from the Strategic Health Innovation Partnerships of the Medical Research Council (MRC) for a study entitled “Systems immunology of ID93 vaccine-induced protection against recurrent TB disease”.

The study, which “*will identify correlates of risk of TB disease, TB treatment success and vaccine induced protection against recurrent TB*”, is significant because it will contribute to knowledge

about the biology underlying the progression to TB or successful TB treatment.


An important element of the study will be to look at particular immunological areas that help to predict whether someone will develop TB or whether they will have successful TB treatment. According to Associate Professor Scriba “*the research will ultimately allow us to conduct an analysis to determine what type of immune response is required for the ID93 vaccine to protect.*”

The contract, which had been signed during August with the South African Medical Research Council (MRC), through their Strategic Health Innovation Partnerships (SHIP) unit, will extend over a period of three years and will involve a consortia of researchers including Associate Prof. Mark Hatherill from SATVI; Prof. Gerhard Walzl of the Immunology Research Group, Tygerberg (University of Stellenbosch); Prof. Linda Gail Bekker of the Desmond Tutu HIV Centre (University of Cape Town); Dr Nesri Padayatchi, Dr Kogieleum Naidoo and Dr Lyle McKinnon from the Centre for the AIDS Programme of Research in South Africa (CAPRISA); Dr Daniel Zak from Seattle Biomedical Research Institute and Professors Steve Reed and Rhea Coler from the Infectious Disease Research Institute.

CARINA'S CHOICE NOW AVAILABLE ONLINE

Carina choice now on DVD

A video Production of Carina's Choice, the Wellcome Trust funded comic production, has been produced and is now available online. The drama production, based on the comic book, previously produced by SATVI, took the play, using high school learners as actors, to eight (8) high schools in the Worcester area and has reached about 8000 adolescents over four weeks in 2013. The play depicts a young mother's decision to enrol her baby as a participant in a TB vaccine trial. The young performers were mentored and coached by UCT Drama school students. Audience members all completed pre- and post- test knowledge assessments to measure the production's impact. The video recording of the play can be downloaded from the SATVI website at www.satvi.uct.ac.za. Visit the SATVI video gallery.



JUNE 2014: SATVI TEAM MAKES IMPACT AT 4TH TB CONFERENCE-



Dr Michele Tameris

Dr Adam Penn-Nicholson

In delivering the keynote address at the recent TB Conference in Durban, former SATVI Director and now Deputy Director of TB Vaccines at the Bill and Melinda Gates Foundation, Professor Willem Hanekom, emphasised the necessity to replace or to improve on the Bacillus Calmette-Guerin (BCG) vaccine and expand on the TB vaccine candidates that SATVI is researching. The aim is the development of vaccines that will work better than the BCG vaccine. Strategies include recombinant live mycobacterial vaccines, recombinant viral vectored vaccines and recombinant protein vaccines. According to him SATVI is also working on introducing better models of testing vaccines so that the quality of the vaccines can be improved.

Associate Professor Tom Scriba addressed a symposium dealing with TB vaccines, with a talk about "Role correlates of risk of TB disease studies in TB vaccine development".

Dr Adam Penn-Nicholson, Postdoctoral Research Fellow, delivered a paper on "Whole Blood transcriptome biomarker of risk of TB diseases in M. tuberculosis

infected adolescent.

ADVOCACY THROUGH DRAMA

Dr Michele Tameris, TB Vaccine Researcher presented a special workshop on the "Use of drama" during the Advocacy through Creative Media and Storytelling Skills Building workshop on the work which SATVI has done in harnessing creative media to create awareness about TB. Through her initiative SATVI has developed a comic Carina's Choice which portrays a young mother who decides to enlist her baby as a subject in a clinical TB vaccine trial. She is met with resistance from her family and friends. Tameris has been the driving force behind this Wellcome Trust funded project, which has now been developed into a play with the support of UCT's Drama Department.

Dr Michele Tameris, presented a poster on the "Local reactogenicity of novel Tuberculosis Vaccine Aeras 402 in healthy infants previously vaccinated with BCG" and through the initiative of the SATVI Executive Committee, this year has also seen two study coordinators, Sisters Michele Van Rooyen and Francis



Sister Michele van Rooyen

Poster presentation accepted for World Lung Conference

Research Nurse, Michele van Rooyen, Vaccine Study Coordinator at the Worcester vaccine research site of the South African Tuberculosis Vaccine Initiative (SATVI), will soon be departing for Spain, where she will be presenting a research poster into the development of BCG lesions, at the World Lung Conference from 28 October to 1 November 2014.

Ratangee presenting posters on "The evolution of the BCG lesion in neonates and adults" and "the importance of school involvement in adolescent TB Vaccine Trials", respectively. Postdoctoral fellow Dr Helen Mearns also presented a poster on the recently completed PATH trial, entitled "Safety, reactogenicity and immunogenicity of BCG administration via a disposable syringe jet injector compared with administration via syringe and needle". The presentation by Van Rooyen has just been accepted for presentation at the World Lung Conference to be held in Barcelona Spain from 28 October to 1 November 2014.

SATVI RECEIVES ACCREDITATION FROM USA CLINICAL TRIAL RESEARCH GROUP



SATVI Director, Associate Professor Mark Hatherill briefing the delegation.



Ms Manizhe Payton Director, DAIDS.



Professor Linda Gail Bekker-Desmond Tutu Aids Foundation.

Scientists at the UCT based South African Tuberculosis Vaccine Initiative (SATVI) were ecstatic with the announcement by the Division of AIDS (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA that SATVI meets its stringent requirements for participation in international clinical trials. On Tuesday 19 August 2014, the DAIDS Branch Chief, Ms Donna Germuda announced that "SATVI has met all the stringent requirements of the DAIDS site approval process".

This approval by DAIDS means that SATVI, as part of the UCT Clinical Trials Unit (UCTCTU) headed by Professor Linda-Gail Bekker, will be able to

participate in DAIDS-funded clinical research for the development of therapies, interventions and strategies to treat and prevent HIV-related tuberculosis co-infection.

According to Associate Professor Mark Hatherill, SATVI Director, he was very pleased with this important milestone which SATVI has just attained. After a recent visit from DAIDS, he noted "It was very clear that our visitors from DAIDS were highly impressed with the professionalism of each and every SATVI staff member they met during the accreditation process".

The driving force behind this complex project, Dr Katrina Downing, told us that "this approval is a fantastic accolade for the SATVI team who

worked on the seven month long application process and who, despite the enormity of the application process, remained focused, enthusiastic and dedicated. SATVI will now be able to expand into HIV-related clinical trials. According to her, the next exciting step, will be the site activation by the AIDS Clinical Trials Group (ACTG), a clinical trial network of DAIDS.

Mrs Marwou de Kock Field Site Manager, said she was excited about the reward which has come at the end of this long process to get accredited. "I'm so proud to be working with such a wonderful group of people!"

UPDATE ON BOLAND RESEARCH COMMUNITY ADVISORY BOARD



Boland Research Community
Advisory Board



CAB Meeting
23 July 2014



CAB Meeting
23 August 2014



Chairperson of CAB,
Mrs Belinda Ameterra



CAB members completed training
in Good Clinical Practice (GCP).

The Boland Research Community Advisory Board (BRCAB) has been very active the past few months holding meetings during July, August and September. During the past two meetings the CAB has finalised its Constitution, a corporate logo (see logo above) and is participating in the ACTG network. During the last CAB meeting on Saturday 23 August 2014, SATVI Principal Investigator, Dr Hennie Geldenhuys shared the progress SATVI had made with clinical trials. The CAB, which is being supported by Reverend David Galetta, Global Co-Chair since 2011, recipient of the HVTN's Network Citizen Award for demonstrated exemplary leadership and dedication in the HVTN (HIV Trials Vaccine Network).

PLANNED CAB MEETINGS FOR 2014:

18 October 2014 and 22 November 2014

SATVI COLLABORATES WITH THE UNIVERSITY OF WASHINGTON



Dr Angelique Luabeya (Principal Investigator); Mrs Marwou de Kock (Site Manager); Professor Jerry Cangelosi (University of Washington); Mrs Elizabeth Filander (Nurse); Mrs Amaryl Van Schalkwyk (Surveillance Officer) and Community Research Workers; Ms Cindy Elbring and Mr Petrus Tyambetyu.

On Thursday 18 September 2014, Professor Jerry Cangelosi, Head of Environmental and Occupational Health Sciences from the University of Washington visited SATVI and met up with the SATVI team who collaborated with him on the Home based Assessment of Exposure (HBAE) study.

SATVI DEVELOPS TRAINING PROGRAM TO EXPOSE CHILDREN TO THE WORLD OF TB RESEARCH



Lwazi Fanana, Ndilisa May Monwabisi
Mkungela Visit Labs. Photo: EH!WoZA

Talita Maliti talking about how TB has affected
her and her family. Photo: EH WOZA

Ms Anastacia Koch; Drs Virginie Rozot; Adam Penn-
Nicholson; Elisa Nemes; Sara Suliman and Helen Mearns

For more information visit:

<http://cargocollective.com/ehwoza/>

<http://blogs.plos.org/speakingofmedicine/2014/06/12/ehwoza-leaving-lab-addressing-tb-stigmas-taboos/>

In a unique collaboration between five research units attached to the Institute of Infectious Disease and Molecular Medicine (IDM) in the Faculty of Health Sciences, research laboratory staff have joined forces in developing and rolling out a training program that empowers children with knowledge about the biomedical world and practical media skills. The public engagement program, funded by the Wellcome Trust, was developed by IDM students Anastasia Koch, Zanele Ditse, Olivia Carulei and Hanif Esmail, in close collaboration with local artists Ed Young and Herman de Klerk, with the support of staff from the South African Tuberculosis Vaccine Initiative (SATVI), the Clinical Infectious Diseases Research Initiative (CIDRI), the Desmond Tutu HIV Centre (DTHC) and the Molecular Mycobacteriology Research Unit (MMRU).

According to Anastasia Koch, PhD student attached to the Molecular Mycobacteriology Research Unit of the University of Cape Town, "the

project started in an organic, informal way as part of the UCT Post-Graduate Student Council, in collaboration with Ikamva Youth, who provide extra-curricular tutoring to children in Khayelitsha. Seed funding from the MMRU kick-started the project and facilitated production of a pilot documentary which greatly strengthened the Wellcome proposal. The program was structured so that specialists within the IDM could be drawn into the program, which has already resulted in a greater awareness about Tuberculosis (TB) and HIV amongst children."

The SATVI team, consisting of Dr Elisa Nemes, Dr Sara Suliman, Dr Helen Mearns, Dr Virginie Rozot, Dr One Dintwe, Drs Adam Penn-Nicholson and Erica Smit developed a section on TB vaccinology, that was presented in an interactive and fun way to children. The training program covered vaccines, how they work, the history and application of the BCG-TB vaccine, the importance of clinical trials, ethics, basic

immunology, as well as a practical session in the SATVI laboratory. During the program, learners were shown a film version of Carina's Choice, a World Health Organisation (WHO) funded public engagement initiative developed by SATVI.

Dr Virginie Rozot, SATVI Research Fellow, told us that "as part of the training program, children were exposed to the laboratory environment of SATVI in a practical way, working with pipettes and even wearing their own lab coats."

The program put children through five (5) scientific workshops after which they were equipped with cameras to film in the community, followed by training to create short films out of their video footage. Through the program, children have been exposed to hot topics in TB, the cutting edge of the TB and biomedical research field and then sent out into the community. Using this scientific basis, learners will be able to film and document what they believe contributes to TB in their community.

NEW STAFF AND STUDENTS INTRODUCED TO SATVI

Staff and student induction 11 July 2014

Visit to Trials House




On Friday 11 July 2014 the Worcester site of SATVI hosted a delegation of staff and students, who had joined this TB vaccine research organisation over the past six months. The intake, of staff at various levels and students ranging from Masters to PHD level, were shown around the Worcester Vaccine Trial site which includes (4) vaccine testing sites, a Pharmacy, a Laboratory, as well as surveillance, logistics and data management sections

Worcester Laboratory



Laboratory Manager Mr Simba Mabwe

Pharmacist Mrs Carolyn Jones addressing students and staff.



Principal Investigator Dr Hennie Geldenhuys talking to students about the vaccine site.

Sister Elisma Coetsee addressing staff and students

Sister Pietersen at Empilsweni Clinic, Worcester.

Appointments- June - September 2014



Pamela Mangala Laboratory Technologist Worcester	Sindile Matiwane Laboratory Technologist Cape Town	Fadia Alexander Laboratory Technologist Cape Town	Maria Jacobs Enrolled Nurse Worcester	Portia Dlakavu Laboratory Technologist Worcester	Kelvin Vollenhoven Communications and Marketing	Yolundi Cloete Laboratory Quality Assurance
---	---	--	--	---	---	---

Staff Training

Logistics Staff complete Course in Handling Dangerous Goods



On Tuesday 1 July 2014 officials attached to the Logistics Department of the Worcester SATVI site successfully completed a course in Handling Dangerous Goods. Staff working in the Logistics Department are required to complete this course annually because in the course of their duties they are

exposed to dangerous chemicals and materials. From left to right: Mr Maigan Ratangee- Head Logistics Officer; Mr Werner Swanepoel Breërvier Training; Mr Clive Macqubela; Mr Phumxile Langata; Mr Henry Issel and Mr Abie Pretorius Logistics Officers.

Staff Wellbeing



Elma Van Rooyen (Third prize), Yulandi Herselman (First prize) and Charmaine Abrahams (Second prize).

The results of hours of strenuous exercise, adjusting eating plans, regular talks with the dietician and monthly weigh-in's with the Quinn Health nurse have paid off for SATVI Worcester staff. During June 2014, SATVI Worcester staff had their final weigh in session and showed a combined weight loss of 60 kgs, which translates into 459 cm lost. According to Mrs Marwou De Kock, SATVI Field Site Manager, the SATVI Lifestyle Challenge programme was introduced in February 2014 as an initiative via UCT HR Health and Wellness and PSG, a Healthcare

intermediary and supported by Dr Zameer Brey, Chief Operating Officer. SATVI staff who often work long and irregular hours, however still found the time in their busy schedules to achieve their health goals. SATVI, in conjunction with PSG, the healthcare intermediary supported the program with a dietician, professional nurse and a personal trainer. According Mrs Yulandi Herselman, who was the winner of the Fitness Challenge, she joined the programme to make a change in her personal lifestyle and lost 9.6 kilograms as direct result of her participation in

the program. She enjoyed meeting with the other staff members in the kitchen where they discussed and shared their eating plans, shared recipes and ideas to stick to the program. Mrs Sunelza Lakay, one of the thirty six participants who started with the challenge in February 2014, said that she enjoyed the challenge, because the program was an important way to change her eating habits. The group train Tuesdays, Wednesdays and Thursdays at the SATVI premises. Contact Garth Faroo at 072 524 1173

Diarize SATVI Wellness Day – 28 November 2014

STAFF TEAMBUILDING 8 August 2014



The SATVI team, well known for the fast pace at which they work, recently held a staff team building session in Constantia at the Abranch Teambuilding Centre.



Team Silver



Team Blue



Team Black



Team Green



Team Red



Team Purple



Team Pink



Team Orange



Mark Hatherill; Juanita Ferreira; Henry Isset and Yulandi Herselman



FAREWELL TO WILLEM HANEKOM



RESEARCH PUBLICATIONS-

January - September 2014

Most recent academic research papers published by SATVI authors January-September 2014:

	Title	Authors	Impact Factor
1	Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study	Johnson L, Geldenhuis H, Thiel BA, Toefy A, Suliman S, Pienaar B, Chheng P, Scriba T, Boom WH, Hanekom W, Hatherill M, Hanekom W	5.854
2	Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.	Lutwama F, Kagina BM, Wajja A, Waisma F, Mansoor N, Kirimunda S, Hughes EJ, Kiwanuka N, Joloba ML, Musoke P, Scriba TJ, Mayanja-Kizza H, Day CL, Hanekom W	5.848
3	Maturation of Innate Responses to Mycobacteria over the First Nine Months of Life.	Shey MS, Nemes E, Whatney W, de Kock M, Africa H, Barnard C, van Rooyen M, Stone L, Riou C, Kollmann T, Hawn TR, Scriba TJ, Hanekom W	5.52
4	Differential gene expression of activating Fc γ receptor classifies active tuberculosis regardless of human immunodeficiency virus status or ethnicity.	Sutherland JS, Loxton AG, Haks MC, Kassa D, Ambrose L, Lee JS, Ran L, van Baarle D, Maertzdorf J, Howe R, Mayanja-Kizza H, Boom WH, Thiel BA, Crampin AC, Hanekom W, Ota MO, Dockrell H, Walzl G, Kaufmann SH, Ottenhoff TH,	4.578
5	Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between moxifloxacin and ofloxacin in African patients.	Zvada SP, Denti P, Sirgel FA, Chigutsa E, Hatherill M, Charalambous S, Mungofa S, Wiesner L, Simonsson US, Jindani A, Harrison T, McIlleron HM	4.565
6	The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.	Tameris M, Geldenhuis H, Luabeya KK, Smit E, Hughes JE, Vermaak S, Hanekom W, Hatherill M, Mahomed H, Mac Shane H, Scriba TJ	3.73
7	Patients with Tuberculosis Disease Have Mycobacterium tuberculosis-Specific CD8 T Cells with a Pro-Apoptotic Phenotype and Impaired Proliferative Capacity, Which Is Not Restored following Treatment.	Day CL, Moshi ND, Abrahams DA, van Rooyen M, O'rie T, de Kock M, Hanekom WA	3.73
8	Time to Symptom Resolution in Young Children Treated for Pulmonary Tuberculosis.	Mpofu N, Moyo S, Mulenga H, Luabeya KK, Tameris M, Geldenhuis H, Hussey G, Scriba T, Hanekom W, Mahomed H, Hatherill M.	3.569
9	The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responses.	Kagina BM, Tameris MD, Geldenhuis H, Hatherill M, Abel B, Hussey GD, Scriba TJ, Mahomed H, Sadoff JC, Hanekom WA;	3.492
10	Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.	Hatherill M, Geldenhuis H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom W, Johnson JL.	3.492
11	Inflammatory and myeloid-associated gene expression before and one day after infant vaccination with MVA85A correlates with induction of a T cell response.	Matsumiya M, Harris SA, Satti I, Stockdale L, Tanner R, O'Shea MK, Tameris M, Mahomed H, Hatherill M, Scriba TJ, Hanekom W, Mc Shane H, Fletcher HA	3.025
12	A controlled trial of sputum induction and routine collection methods for TB diagnosis in a South African community.	Geldenhuis H, Whitelaw A, Tameris MD, Van As D, Luabeya KK, Mahomed H, Hussey G, Hanekom W, Hatherill M	3.024
13	Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A.	Harris SA, Satti I, Matsumiya M, Stockdale L, Chomka A, Tanner R, O'Shea MK, Manjaly Thomas ZR, Tameris M, Mahomed H, Scriba TJ, Hanekom WA, Fletcher HA, Mc Shane H	2.598
14	Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.	Lutwama F, Kagina BM, Wajja A, Waisma F, Mansoor N, Kirimunda S, Hughes EJ, Kiwanuka N, Joloba M, Musoke P, Scriba TJ, Mayanja-Kizza H, Day CL, Hanekom WA	2.357
15	Pediatric intensive care in South Africa: an account of making optimum use of limited resources at the Red Cross War Memorial Children's Hospital.	Argent AC, Ahrens J, Morrow BM, Reynolds LG, Hatherill M, Salie S, Benatar SR.	2.354

The Adventures of DUDLEY

By: Debbie Abrahams

THE SATVI BEAR



Hello everyone. My name is Dudley the SATVI Teddy Bear. I like climbing fruit trees and meeting new people. But my day job involves raising TB awareness in First World countries. I recently went to London and did just that.

I travelled all the way from Cape Town to London in England.

The train was so full on our journey into London that I had to stand the whole way and hung onto the safety straps for dear life.



My first stop was to tell my friends in Harrods. They were all very interested in the work we do so diligently at SATVI. I was proud to speak about all we do. They said to tell you all to keep up the good work



Next, I went to a department store and while Debbie was shopping (actually just looking because seriously? She can afford it?), I spoke to the shop assistant who was also very interested in our valiant efforts to fight TB.

Next it was off to Oxford to see some sights because all work and no play makes Dudley a dull boy!



I visited the Covered Market in Oxford.

I visited St Marys which is a Parish church and has been the official church of Oxford University since the 1200's

Next I visited St. Mary's which is a parish church and has been the official church of the University of Oxford since the 1200s

The Adventures of DUDLEY



Alas, sight seeing had to come to an end as I made my way to meet Samantha Vermaak who works with Helen McShane. Samantha is the TB Vaccine Program Manager at the Centre for Clinical Vaccinology and Tropical Medicine at the Jenner Institute at Oxford University. She kindly showed me what they are busy with at Oxford University. We had a wonderful chat about how much progress we are making in our efforts to fight TB. I enjoyed my time with her.



But as with all good things, they must come to an end. Soon I had to make my way home after a very satisfying outing to tell as many people as possible about what we do at SATVI.

DUDLEY THE SATVI BEAR

We spoke to Debbie Abrahams, Laboratory Technologist about her ideas for Dudley, the SATVI mascot.

Briefly tell us about your concept.

My concept is for the development of a teddy bear, Dudley as a mascot for SATVI. During a recent trip to London, I thought about doing something to raise TB awareness in first world countries because everyone I spoke to in London found TB to be a very vague disease and something that didn't affect them at all. They only thought about the freedom of movement within EU states as an economic issue and NOT an infectious disease

issue."

After whom is he named?

I have named the Teddy bear after Greg Hussey, whose second name is Dudley and who being a very humble person, I thought we could name (with his permission) him after as the founder of SATVI. My hope with this idea is that Dudley can be used to approach strangers to spark a conversation about TB



Debbie Abrahams and Dudley

If you have a job for Dudley or a destination where he can go and share the good work that SATVI does, contact Debbie or Kelvin.

Bright Sparks Winner AUGUST 2014



Winner: Mrs Susan Rossouw:
Participant Armbands to promote
participant retention

The winner of the SATVI Bright Sparks Award for innovative ideas was recently announced at the Quarterly SATVI Staff meeting. According to SATVI Director, Associate Professor Mark Hatherill, the Bright Sparks Award Program was established to create and nurture innovation amongst SATVI staff. Marwou De

Kock, Field Site Manager told us that some of the previous innovation ideas which have been implemented were an enhanced ordering system, program to promote an active lifestyle, establishment of Whats Ap Chatgroups as well as marketing activations at the local shopping mall.



SATVI SUPPORTS LOCAL COMMUNITY ORGANISATIONS



Pionier Hostel rooms get revamp



Before



After

In celebration of Mandela Day, staff from the South African Tuberculosis Vaccine Initiative (SATVI), did their bit with a generous donation of equipment, material and time to the Worcester-based Sean Kelly Centre for Multiple Disabled Children, Pionier School for Blind and the Thuthuzela Centre for Victims of Violence. At Sean Kelly Centre for Multiple Sensory Disabled, the group handed over toys, personal toiletries, sweet parcels, tracksuits, fleecy blankets and a DVD player.

The Thuthuzela Care Centre, which provides victim support to victims of domestic violence, received personal toiletries, underwear, coffee, tea and sugar, sweet parcels, whilst the Pioneer Hostel for the Blind, received a makeover with sheets, pillow cases, pillows, comforters. The donation was complemented by a music sound system, a dvd player, shower curtains. Staff had made up table cloths in their own time at their homes. SATVI has made a commitment through management and its staff to support local organisations, not just on Mandela Day, but on a sustainable basis.

Post Doctoral Fellow appointed as Research Officer



Doctor Elisa Nemes, Post-doctoral Fellow at SATVI, has been appointed as Research Officer at SATVI. In her new responsibilities she will actively engage in all aspects of the research process independently, including conducting and overseeing research projects (immunology and clinical trials), publication of results, applying for and managing research grants and supervision of postgraduate students.

SATVI Immunology Head Amongst Top UCT Researchers

Associate Professor Thomas Scriba, was one of eleven UCT researchers selected as finalists in the **NSTFBHP Biliton Awards for 2013/2014**. Scriba is Associate Professor and Departmental Director of Immunology, SA Tuberculosis Initiative (SATVI). His research focuses on the immune response to tuberculosis, with a particular emphasis on translational research into new and improved TB vaccines. He has been co-investigator for more than 10 clinical trials of new TB vaccines and has authored more than 50 papers in peer-reviewed international scientific journals. Scriba has successfully raised research funds from the Wellcome Trust, EDCTP, Bill and Melinda Gates Foundation and Department of Science and Technology, amongst others" and has supervised many postgraduate students. He serves on several international TB vaccine advisory groups.



SATVI has a world-beating track record of successful TB vaccine trials, coupled with highly innovative TB immunology studies, which together are responsible for the group's increased publication output in high impact journals- *Associate Professor Mark Hatherill- SATVI Director*

VISIT FROM UNIVERSITY STELLENBOSCH



On 19 June 2014 Dr Fanie Malherbe and colleagues from the Immunology Research Group at the University Stellenbosch visited SATVI to learn about its operations.

SATVI PHARMACY ATTAINS A RATING



Satvi's Pharmacy has attained an A grading from the South African Pharmacy Council. Susan Rossouw, the responsible pharmacist, explained that the A grade certificate was awarded to Satvi's Pharmacy after a rigorous inspection of all processes, equipment and staff by the SAPC in February 2014.

From left to right: Mrs Natasja Botes, Mrs Carolyn Jones; Mrs Susan Rossouw and Mrs Sandra Goliath

Interesting facts about SATVI

Did you know?

- SATVI's first name was the BCG Studies.
- SATVI was established in 2001 by Professor Greg Hussey.
- The TB incidence rate in Worcester is 1400/100 000 people.



Delegation from Bill Gates Foundation visits SATVI

From left to right Ms Becky Bartlein (Program Manager), Mrs Marwou de Kock, Ms Mariah Richardson (Program Coordinator), Dr Michele Tameris (Principal Investigator) and Dr Adam Penn-Nicholson (Postdoctoral Research Fellow).

On the 29th August 2014, a senior delegation from the Bill and Melinda Gates Foundation, one of SATVI's donors, paid a visit to SATVI's offices in Cape Town and Worcester, to gain insight into the work that SATVI does.



SATVI Study Coordinator, Sister Frances Ratangee addressing Ms Mariah Richardson and Ms Becky Bartlein .

BILL & MELINDA
GATES foundation

"We're both optimists. We believe by doing these things—focusing on a few big goals and working with our partners on innovative solutions—we can help every person get the chance to live a healthy, productive life"

Bill and Melinda Gates

Raising awareness about TB



On Friday 20 September 2014 Dr Angelique Luabeya (Principal Investigator) addressed a group of social workers on the signs and symptoms of TB.

Facebook

We have created a Facebook Page for SATVI and use it to communicate our achievements, social news and general developments in the TB research community. Click to like our Page.

WWW.FACEBOOK.COM/SATVIUCT

ROOI ROSE CANSA TEA- 20 SEPTEMBER 2014



On Saturday 20 September 2014, staff from SATVI participated in the Rooi Rose Kansa tea organised by CANSA in Stellenbosch. CANSA, is an organisation that conducts awareness programmes, patient care around cancer.



The SATVI newsletter will be published quarterly and will reflect the work, the achievements and the people who make SATVI such a dynamic organisation within the broader UCT and TB research community. If you have any suggestions, achievements, ideas for stories to build the SATVI narrative, please submit to : Via email: kelvin.vollenhoven@uct.ac.za or SMS to 074 585 2858 or telephone at 023-346 5400

"Driving Research for Human Health in Africa"



TEN - YEAR ANNIVERSARY SYMPOSIUM

SUNDAY 2 – TUESDAY 4 NOVEMBER 2014

OPENING CEREMONY

Starts at 16h00, Sunday 2 November 2014

The keynote speaker presenting the second 2014 UCT Wolfson Memorial Lecture is

Professor Mark Davis

Howard Hughes Medical Institute, Stanford University School of Medicine

with **Dr Max Price**, Vice Chancellor, University of Cape Town

and **Professor Glenda Gray**, President, South African Medical Research Council

The Opening Ceremony will be followed by a cocktail party. All are welcome to attend.
RSVP required for cocktail party by 28 October – jolandi@onscreenav.co.za

CONFIRMED INVITED SPEAKERS

- **Dr Alan Sher**, Laboratory of Parasitic Diseases, NIAID, National Institutes of Health, USA
- **Professor Alberto Kornblihtt**, University of Buenos Aires, Argentina
- **Dr Charles Rotimi**, Centre for Research on Genomics and Global Health, National Institutes of Health, USA
- **Professor Lynn Morris**, National Institute for Communicable Diseases, Johannesburg
- **Professor Deenan Pillay**, Africa Centre for Health & Population Studies, University of KwaZulu-Natal
- **Dr Musa Mhlanga**, Gene Expression and Biophysics Group, Council for Scientific & Industrial Research, Pretoria
- **Professor Salim Abdool Karim**, CAPRISA, University of KwaZulu-Natal & outgoing MRC President



All interested parties welcome to attend, at no charge

For more information: Heather.Davies-Coleman@uct.ac.za

Wolfson Pavilion, Institute of Infectious Disease & Molecular Medicine,
Faculty of Health Sciences, University of Cape Town